AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9597052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in normotensive patients)
Number of subjects: 341
Study 9316673 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa/benserazide
Number of subjects: 21
Study 9316673 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 21
Study 2465445 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-OH-HQ 225 mg
Number of subjects: 12
Study 2465445 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-OH-HQ 450 mg
Number of subjects: 12
Study 2465445 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-OH-HQ 900 mg
Number of subjects: 12
Study 2465445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28333698 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System (PHP)
Number of subjects: 475
Study 28333698 — intervention group
Group type: COMPARATOR
Intervention: Control (Injury Prevention Survey)
Number of subjects: 475
Study 29144152 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 158
Study 29144152 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and psychological treatment
Number of subjects: 158
Study 26706860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation intervention (12 sessions over 4 weeks)
Number of subjects: 46
Study 26706860 — intervention group
Group type: COMPARATOR
Intervention: Standard drug and non-drug antidepressive treatment (control group)
Number of subjects: 46
Study 24749303 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 90
Study 24749303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar paravertebral block (PVB)
Number of subjects: 90
Study 24749303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pain relief)
Number of subjects: 90
Study 23642001 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor neighborhood physical conditions
Number of subjects: 261
Study 23642001 — intervention group
Group type: EXPERIMENTAL
Intervention: Average level of behavior problems of neighborhood peers within 255 meters
Number of subjects: 261
Study 20176914 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Latinas (BA-Latino or BAL)
Number of subjects: 10
Study 18078762 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (POC)
Number of subjects: 50
Study 15677609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 9
Study 15677609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12652886 — intervention group
Group type: EXPERIMENTAL
Intervention: Scutellaria lateriflora
Number of subjects: 0
Study 12652886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10644567 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐8 (2 ng. kg(‐1). min(‐1))
Number of subjects: 7
Study 10644567 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 8876264 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day prednisolone
Number of subjects: 20
Study 8876264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1615179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (5 mg) as one puff q.d.s. via inhaler
Number of subjects: 16
Study 1615179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6380212 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 12 mg/kg
Number of subjects: 43
Study 6380212 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital 4 mg/kg
Number of subjects: 43
Study 6380212 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital 8 mg/kg
Number of subjects: 43
Study 6380212 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg/kg)
Number of subjects: 43
Study 30686386 — intervention group
Group type: EXPERIMENTAL
Intervention: THP peer-delivered (THPP) and enhanced usual care (EUC)
Number of subjects: 570
Study 30686386 — intervention group
Group type: COMPARATOR
Intervention: EUC only
Number of subjects: 570
Study 29161199 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (64 μg/mL) twice daily for 6 weeks
Number of subjects: 60
Study 29161199 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 60
Study 29161199 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 60
Study 26891216 — intervention group
Group type: EXPERIMENTAL
Intervention: Black raspberry (750 mg/day)
Number of subjects: 51
Study 24532599 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-rich HF meal
Number of subjects: 15
Study 24532599 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich HF meal
Number of subjects: 15
Study 24532599 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich HF meal
Number of subjects: 15
Study 22992411 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress perfusion cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 0
Study 22992411 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography and fractional flow reserve measurements
Number of subjects: 0
Study 21062502 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-defined GERD (mild heartburn and/or regurgitation ≥2 days/week, or moderate/severe heartburn and/or regurgitation ≥1 day/week)
Number of subjects: 16091
Study 21062502 — intervention group
Group type: EXPERIMENTAL
Intervention: Troublesome reflux symptoms
Number of subjects: 16091
Study 21062502 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux symptoms below the threshold for symptom-defined GERD
Number of subjects: 16091
Study 21062502 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-defined GERD
Number of subjects: 16091
Study 21062502 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom frequency and severity approaching the threshold for symptom-defined GERD
Number of subjects: 16091
Study 18080054 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy (COT) with rabeprazole 20 mg
Number of subjects: 268
Study 18080054 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy (ODT) with rabeprazole 20 mg
Number of subjects: 268
Study 15620955 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
Number of subjects: 104
Study 12168126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml line-clearing volume
Number of subjects: 12
Study 12168126 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 ml line-clearing volume
Number of subjects: 12
Study 12168126 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 ml line-clearing volume
Number of subjects: 12
Study 11776799 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT
Number of subjects: 64
Study 11776799 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 64
Study 7876649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 6 months
Number of subjects: 151
Study 7876649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 12 months
Number of subjects: 151
Study 7876649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HM175)
Number of subjects: 151
Study 2361813 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg daily)
Number of subjects: 11
Study 2361813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 362571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 30
Study 362571 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 30
Study 31200952 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation support using a whole‐ward approach for advance care planning
Number of subjects: 0
Study 28459402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation guided by transpulmonary pressure (Ptp) of 20 cmH2O
Number of subjects: 67
Study 28459402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation guided by transpulmonary pressure (Ptp) of 10 cmH2O
Number of subjects: 67
Study 28459402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation guided by transpulmonary pressure (Ptp) of 15 cmH2O
Number of subjects: 67
Study 28459402 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilated by guidance of ARDSNet)
Number of subjects: 67
Study 28459402 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation
Number of subjects: 67
Study 28459402 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 67
Study 28459402 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day mortality
Number of subjects: 67
Study 25567119 — intervention group
Group type: EXPERIMENTAL
Intervention: KD-287 (JE-VC)
Number of subjects: 205
Study 25567119 — intervention group
Group type: COMPARATOR
Intervention: JEV-GCC (JE-MB)
Number of subjects: 205
Study 23464715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral synbiotic (Agri-King Synbiotic, AKSB)
Number of subjects: 196
Study 23464715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 23464715 — intervention group
Group type: EXPERIMENTAL
Intervention: AKSB
Number of subjects: 196
Study 20890244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg monthly) plus PDT
Number of subjects: 162
Study 20890244 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 162
Study 19660610 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus Fenofibrate (20 mg simvastatin + 160 mg fenofibrate)
Number of subjects: 594
Study 19660610 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy (20 mg)
Number of subjects: 594
Study 16750735 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 16750735 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 30
Study 14718691 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening with the Adverse Events Profile (AEP)
Number of subjects: 62
Study 14718691 — intervention group
Group type: COMPARATOR
Intervention: Usual care without the AEP
Number of subjects: 62
Study 14718691 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening with the AEP
Number of subjects: 62
Study 10931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopsy group with acute myocardial infarction (MI)
Number of subjects: 171
Study 10931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with significant coronary artery disease (CAD)
Number of subjects: 171
Study 10931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died of myocardial failure
Number of subjects: 171
Study 10931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CAD patients
Number of subjects: 171
Study 10931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopsied group with acute MI
Number of subjects: 171
Study 9333106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 100 mg t.i.d.
Number of subjects: 36
Study 9333106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg t.i.d.
Number of subjects: 36
Study 9333106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 400 mg t.i.d.
Number of subjects: 36
Study 9333106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 800 mg t.i.d.
Number of subjects: 36
Study 9333106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (all dosages)
Number of subjects: 36
Study 9333106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8489751 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonova (20 micrograms levonorgestrel daily)
Number of subjects: 1821
Study 8489751 — intervention group
Group type: COMPARATOR
Intervention: Cu-T IUDs
Number of subjects: 1821
Study 2426932 — intervention group
Group type: EXPERIMENTAL
Intervention: Allylestrenol (AE)
Number of subjects: 0
Study 2426932 — intervention group
Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA)
Number of subjects: 0
Study 30642387 — intervention group
Group type: EXPERIMENTAL
Intervention: WELCOME-IdA intervention (dementia-specific case conferences)
Number of subjects: 6
Study 28604115 — intervention group
Group type: EXPERIMENTAL
Intervention: xyloglucan-based nasal spray
Number of subjects: 40
Study 28604115 — intervention group
Group type: COMPARATOR
Intervention: saline nasal spray
Number of subjects: 40
Study 25888571 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic CVC-related thrombosis
Number of subjects: 168
Study 25888571 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count >10.6 × 10^9/L
Number of subjects: 168
Study 25888571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean FVIII activity
Number of subjects: 168
Study 25888571 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 >12.2 IU/mL
Number of subjects: 168
Study 25888571 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC-related infections
Number of subjects: 168
Study 24021286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle counseling (five face-to-face sessions and telephone contact over one year)
Number of subjects: 74
Study 24021286 — intervention group
Group type: COMPARATOR
Intervention: Standard medical advice (control group)
Number of subjects: 74
Study 24021286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle counseling
Number of subjects: 74
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release 600 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40-160 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40-120 mg/d
Number of subjects: 0
Study 22776634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 22776634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19820238 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose regimens in RCTs
Number of subjects: 0
Study 19820238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18572996 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Initiative (PI) training program
Number of subjects: 0
Study 18572996 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stress management program
Number of subjects: 0
Study 18572996 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 16097981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NO donor)
Number of subjects: 10
Study 16097981 — intervention group
Group type: COMPARATOR
Intervention: Control experimental series
Number of subjects: 10
Study 11934658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with gestodene
Number of subjects: 274
Study 11934658 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol combined with gestodene
Number of subjects: 274
Study 11934658 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazine, estrone sulfate in combination with norethisterone
Number of subjects: 274
Study 11934658 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol and 1 mg norethisterone acetate
Number of subjects: 274
Study 11934658 — intervention group
Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 274
Study 9971865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 183
Study 9971865 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (Control)
Number of subjects: 183
Study 9971865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 183
Study 7540071 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 alone
Number of subjects: 18
Study 7540071 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 plus methylprednisolone
Number of subjects: 18
Study 7540071 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 plus methotrexate (MTX)
Number of subjects: 18
Study 7540071 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 18
Study 7540071 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 18
Study 7540071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year disease-free survival
Number of subjects: 18
Study 2189248 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil at 200 mg/d combined with sulphafurazole at 25 mg/kg/d
Number of subjects: 0
Study 2189248 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil at 200 mg/d combined with sulphamethoxazole at 25 mg/kg/d
Number of subjects: 0
Study 2189248 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil at 200 mg/d combined with sulphamethoxazole at 10 mg/kg/d
Number of subjects: 0
Study 2189248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6769420 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 194
Study 6769420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 194
Study 31502893 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg
Number of subjects: 2
Study 31502893 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg
Number of subjects: 2
Study 31256092 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor rehabilitation plus cognitive intervention (G1)
Number of subjects: 0
Study 31256092 — intervention group
Group type: COMPARATOR
Intervention: Motor rehabilitation only (G2)
Number of subjects: 0
Study 28379056 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute AL-TENS application
Number of subjects: 11
Study 28379056 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute AL-TENS application
Number of subjects: 11
Study 28379056 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 15-minute vs 30-minute AL-TENS
Number of subjects: 11
Study 25498838 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT plans established after September 2011
Number of subjects: 66
Study 25498838 — intervention group
Group type: COMPARATOR
Intervention: SBRT plans established before September 2011
Number of subjects: 66
Study 23966214 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-managed condition
Number of subjects: 0
Study 23966214 — intervention group
Group type: COMPARATOR
Intervention: Patient-managed condition
Number of subjects: 0
Study 23966214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES practices
Number of subjects: 0
Study 23966214 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-high SES practices
Number of subjects: 0
Study 23966214 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Dutch practice
Number of subjects: 0
Study 21392600 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 850
Study 21392600 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 850
Study 19151304 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 70
Study 19151304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch solution
Number of subjects: 70
Study 19151304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 70
Study 17264336 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) and radiotherapy (RT)
Number of subjects: 716
Study 17264336 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (CT) followed by radiotherapy (RT)
Number of subjects: 716
Study 15525879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day)
Number of subjects: 24
Study 15525879 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg/day)
Number of subjects: 24
Study 11292041 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain resistance exercises (3 sessions per week for 4 weeks)
Number of subjects: 37
Study 11292041 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain resistance exercises (3 sessions per week for 4 weeks)
Number of subjects: 37
Study 11292041 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured leg (both exercise groups)
Number of subjects: 37
Study 9329641 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg vitamin C/day
Number of subjects: 48
Study 9329641 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g vitamin C/day
Number of subjects: 48
Study 9329641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9329641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (both doses)
Number of subjects: 48
Study 8172789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m2 every three weeks, escalating to a maximum of 140 mg/m2)
Number of subjects: 70
Study 8172789 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (500 mg/m2 days 1‐5 every three weeks, escalating to a maximum of 700 mg/m2)
Number of subjects: 70
Study 8172789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 70
Study 8172789 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 70
Study 3359786 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standardized breakfast
Number of subjects: 12
Study 3359786 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal
Number of subjects: 12
Study 29880257 — intervention group
Group type: EXPERIMENTAL
Intervention: KaempMax™ (100 mg daily for 30 days)
Number of subjects: 14
Study 29880257 — intervention group
Group type: EXPERIMENTAL
Intervention: KaempMax™
Number of subjects: 14